OPTIMISE-CKD Drug Utilization - Trial NCT05932901
Access comprehensive clinical trial information for NCT05932901 through Pure Global AI's free database. This phase not specified trial is sponsored by AstraZeneca and is currently Not yet recruiting. The study focuses on Chronic Kidney Disease. Target enrollment is 79432108 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Observational
Sponsor & Location
AstraZeneca
Timeline & Enrollment
N/A
May 04, 2022
Aug 31, 2023
Primary Outcome
Baseline demographics,Baseline clinical characteristics,Baseline comedications,Baseline eGFR in ml/min/1.73m2,Baseline uACR in mg/g,Baseline serum creatinine in mg/dl,Baseline calcium in mg/dl,Baseline sodium in mmol/L,Baseline hemoglobin A1c in %,Baseline hematocrit in %,Baseline systolic blood pressure in mmHg
Summary
This is a multi-national, observational study program using secondary data sources to address
 research questions related to 1) real-world dapagliflozin utilisation in CKD and potential
 for further utilisation, 2), the current CKD treatment landscape and 3) real-world
 effectiveness of dapagliflozin in CKD (pending feasibility assessment).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05932901
Non-Device Trial